血清胸苷激酶1水平的变化在乳腺癌诊断和治疗的应用价值研究  

Application value research on the variation of Serum thymidine kinase 1 for breast cancer diagnosis and treatment

作　　者：伍启康[1] 雷兰芳[1] 黄燕婷[1] 谭智毅[1] 杨洁飞[1] 徐晓丽[1] 

机构地区：[1]佛山市第一人民医院检验科,528000

出　　处：《国际医药卫生导报》2011年第20期2546-2548,共3页International Medicine and Health Guidance News

摘　　要：目的探讨胸苷激酶1（TK1）在乳腺癌诊断和治疗中的应用价值。方法利用酶免疫点印迹化学发光法分别检测205例乳腺癌患者、150例健康体检者的血清TK1浓度，统计阳性率。结果乳腺癌患者未经治疗组TK1平均浓度为2．65pmol／L，其阳性率为67．7％；健康体检者组TK1平均浓度为0．96pmol／L，其阳性率为12．7％，组间比较，差异有极显著性（P〈0．01）;乳腺癌患者治疗缓解组TK1平均浓度以及阳性率与预后不良组及未经治疗组比较，差异有极显著性（P〈0．01）。结论胸苷激酶1在乳腺癌的辅助诊断和治疗过程中的疗效监测及预后判断具有一定的临床应用价值。Objective To explore the application value of thymidine kinase I（TK1） for breast cancer diagnosis and treatment. Methods Serum TK1 concentration and positive rate were detected respectively in 205 patients with breast cancer and 150 healthy cases control with western blot-enhanced chemiluminecence. Results TK1 average concentration of patients with breast cancer in untreated group was 2.65 pmol/L; and its positive rate was 67.7%. TK1 average concentration of healthy control group was 0.96 pmol/L; and its positive rate was 12.7%. There was significant difference（P〈O.O01） among groups. The TK1 average concentration and positive rate had significant difference （P〈0.001） among the breast cancer patients in the remission stage of treatment group, the poor prognosis group, and untreated group. Conclusion TK1 has certain value of clinical applications on breast cancer auxiliary diagnosis, curative effect monitoring during treatment, and prognosis estimate.

关 键 词：胸苷激酶1 乳腺癌 诊断 治疗 

分 类 号：R737[医药卫生—肿瘤]